Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07361367 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants

A Phase 1 study of Healthy Volunteers, sponsored by AbbVie.

Active
Registry status
Phase 1
Development phase
11
Enrollment target
1
Study location

NCT07361367 is a Phase 1 study of Healthy Volunteers that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 11 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07361367, a Phase 1 study of Healthy Volunteers, is active but no longer recruiting, sponsored by AbbVie.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

The objective of this study is to evaluate the PK of a tablet formulation of ABBV-722 under fasted conditions and the effect of food on its bioavailability after administration of single doses

Conditions Studied

Interventions

  • DRUG ABBV-722

Study Locations (1)

Illinois

  • Acpru /Id# 279291 - Grayslake

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2026-01-15
Est. Completion 2026-03
Phase Phase 1

Sponsor

AbbVie

526 total trials

What the Registry Record Tells You About NCT07361367

The ClinicalTrials.gov registry entry for NCT07361367 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which ABBV-722 is the first listed.

NCT07361367 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT07361367 about?

NCT07361367 is a clinical study titled "A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants". The objective of this study is to evaluate the PK of a tablet formulation of ABBV-722 under fasted conditions and the effect of food on its bioavailability after administration of single doses

What is the current status of trial NCT07361367?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2026-01-15. Estimated completion is 2026-03.

What conditions does trial NCT07361367 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT07361367?

The interventions under investigation include: ABBV-722 (DRUG).

Who is sponsoring clinical trial NCT07361367?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07361367 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.